Home › Research › Brain scans and imaging
The clinical prognosis of cognitively unimpaired individuals with positive PET biomarkers
Sylvia Villeneuve. Alzheimer s & Dementia, 2025-12-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Abstract It is a matter of debate if cognitively unimpaired (CU) individuals with Alzheimer pathology should be classified as having Alzheimer's disease, 1 or if this terminology should be restricted to individuals with cognitive impairments. 2 Central to this debate is the uncertainty that all individuals with Alzheimer pathology will develop major cognitive impairments if followed over time. In 2022, two multi‐cohort studies showed that half of CU individuals identified as being abnormal on both amyloid (A+) and tau (T+) positron emission tomography (PET) biomarkers developed mild cognitive impairment (MCI) or dementia when followed for a mean of 3.5 years. 3,4 Individuals only positive on the amyloid scan (A+T‐) were not at increased risk of developing MCI or dementia when compared to A‐T‐ individuals. We recently updated the cognitive status of participants enrolled in one of these studies and found that, with an additional 2.4 years of study follow‐up, 100% of the PREVENT‐AD participants who were A+T+ have now progressed to MCI or dementia (Figure 1). Of high importance, the percentage of progressors in the A+T‐ group increased from 9.09% to 42.42%. These results provide clear evidence that CU older adults with both amyloid plaques and tau aggregates measured with PET will develop cognitive impairments if the disease is not stopped. The deterministic nature of the A+T‐ biomarker group is more ambiguous, but longer follow‐up clearly shows worse prognosis and individuals who are A+T‐ probably have some level of tau pathology even if not yet detectable by tau PET tracers and conventional positivity thresholds. The goal of this presentation is to discuss the prognostic value of amyloid and tau PET biomarkers at identifying CU who will develop MCI in a 6‐year window. We will also discuss new approaches to identify amyloid and tau PET positivity that might be more sensitive than conventional visual read or quantitative binary thresholds. This knowledge is important for enrolling individuals in clinical trials given that some treatments might work best in individuals with low levels of pathology. References 1. Jack, et al., 2024 2. Dubois et al., 2024 3. Strikwerda‐Brown, et al., 2022 4. Ossenkoppele, et al., 2022
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. In cognitively unimpaired older adults who had both amyloid and tau detected on PET scans, all of the PREVENT-AD participants in this group progressed to mild cognitive impairment or dementia with additional follow-up. Reported effect size: 9.09% to 42.42%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Villeneuve, S. (2025). The clinical prognosis of cognitively unimpaired individuals with positive PET biomarkers. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_096588
Vancouver
Villeneuve S. The clinical prognosis of cognitively unimpaired individuals with positive PET biomarkers. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_096588. PMID: 41439799.
BibTeX
@article{villeneuve2025-41439799,
author = {Villeneuve, Sylvia},
title = {{The clinical prognosis of cognitively unimpaired individuals with positive PET biomarkers}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_096588},
pmid = {41439799},
url = {https://doi.org/10.1002/alz70856_096588}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In 2022, two multi‐cohort studies showed that half of CU individuals identified as being abnormal on both amyloid (A+) and tau (T+) positron emission tomography (PET) biomarkers developed mild cognitive impairment (MCI) or dementia when followed for a mean of 3.5 years. 3,4 Individuals only positive on the amyloid scan (A+T‐) were not at increased risk of developing MCI or dementia when compared to A‐T‐ individuals.
- These results provide clear evidence that CU older adults with both amyloid plaques and tau aggregates measured with PET will develop cognitive impairments if the disease is not stopped.
Why it matters
In cognitively unimpaired older adults who had both amyloid and tau detected on PET scans, all of the PREVENT-AD participants in this group progressed to mild cognitive impairment or dementia with additional follow-up. The authors state this shows such individuals will develop cognitive impairment if the disease is not stopped, though this finding comes from one study cohort.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Study designcohort study
- Effect size9.09% to 42.42%
- Evidence strengthModerate
How this study scored 46/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Sylvia Villeneuve: h-index 48 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | McGill University: institution h-index 1,373 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41439799) |
| Free to read | 2 / 2 | Free to read |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70856_096588
- PubMed: 41439799
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Brain scans and imaging from nearby years
Also in Brain scans and imaging
136 studies in the library are filed under Brain scans and imaging with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Brain scans and imaging hub.